Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

The study is being conducted to evaluate the safety and efficacy of tislelizumab combined with GX regimen versus tislelizumab combined with GP regimen in the first-line treatment of nasopharyngeal carcinoma.

Trial Details

NCT ID
NCT06177301
Phase
PHASE3
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • Tislelizumab combined with GX
  • Tislelizumab combined with GP
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Histological or cytological examination confirmed recurrence or metastasis of nasopharyngeal carcinoma;
  • Patients who have not previously received systemic treatment for recurrent or metastatic diseases (For patients who have previously received induct…
  • Age: 18-75 years old, male or female;
  • Perfomance Status: 0\~1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →